Most drugs are metabolized by CYP3A enzymes, and variations in expression levels of these enzymes are believed to determine whether patients will have a positive or adverse drug response.

And this can increase your side effects from Verzenio. CYP3A inducers speed up the removal of Verzenio from your body. And this can make Verzenio less effective for you. These lists don’t ...

When given with known CYP3A inducers (including but not limited to efavirenz, rifampin, carbamazepine, phenobarbital, and phenytoin), the maraviroc dosage should be increased to 600 mg twice daily.

Pregnancy. Nursing mothers. See Contraindications. Concomitant moderate CYP3A inducers: not recommended. May be potentiated by combined P-gp, UGT1A1, and strong CYP3A inhibitors: concomitant use ...

Concomitant strong or moderate CYP3A inducers: Avoid use with Nurtec ODT; may lead to loss of efficacy. Concomitant potent inhibitors of P-gp: Avoid another dose of Nurtec ODT within 48 hours.

Avoid Taking Nurtec ODT If You Are On These Medications Strong CYP3A4 inhibitors, moderate CYP3A4 inhibitors, strong and ...

An Uppthera Inc. patent describes new proteolysis targeting chimera (PROTAC) compounds comprising E3 ubiquitin ligase-binding moiety covalently linked to a serine/threonine-protein kinase PLK1 (STPK13 ...

PT-112, Phosplatin’s lead ICD inducer, is in phase 2 clinical trials for metastatic castration-resistant prostate cancer, and could be applicable to other indications, including rare and ...

Two twice-daily doses of maraviroc have been approved: 150mg dose when used with protease inhibitors (with the exception of tipranavir/ritonavir) or cobicistat 300mg dose when combined with tipranavir ...

Massachusetts Institute of Technology has described proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase-binding agent coupled to cyclin-dependent kinase 9 (CDK9)-targeting ...

The numerous drug interactions with cytochrome P-450 (CYP) isoenzyme inducers and inhibitors, as well as the possibility of liver toxicity, especially in patients with hepatitis or elevated ...

Avoid concomitant use of REZLIDHIA with strong or moderate CYP3A inducers. Avoid concomitant use of REZLIDHIA with sensitive CYP3A substrates unless otherwise instructed in the substrates ...